TCGA-CQ-A4C7-01A-11R-A24Z-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.080593607
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- MYC_TARGETS_V2+0.500
- INTERFERON_ALPHA_RESPONSE+0.360
- HEDGEHOG_SIGNALING+0.350
- MYOGENESIS+0.320
- TGF_BETA_SIGNALING+0.290
- NOTCH_SIGNALING+0.230
- UV_RESPONSE_DN+0.200
- DNA_REPAIR+0.190
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- FATTY_ACID_METABOLISM-0.350
- OXIDATIVE_PHOSPHORYLATION-0.330
- PEROXISOME-0.290
- CHOLESTEROL_HOMEOSTASIS-0.270
- MTORC1_SIGNALING-0.240
- XENOBIOTIC_METABOLISM-0.230
- BILE_ACID_METABOLISM-0.220
- ESTROGEN_RESPONSE_LATE-0.220
- SPERMATOGENESIS-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 218cda38-ec89-4e23-849b-93f1b5bd0655 | — | — | 0.736 |
| 2 | TCGA-CV-6950-01A-11R-1915-07 | — | — | 0.718 |
| 3 | SRR8518161 | — | E | 0.702 |
| 4 | TCGA-34-5239-01A-21R-1820-07 | — | cohortSQ1 | 0.698 |
| 5 | SRR5903555 | — | cohortSQ1 | 0.698 |
| 6 | TCGA-A7-A4SE-01A-11R-A266-07 | — | E | 0.692 |
| 7 | TCGA-AN-A0FD-01A-11R-A034-07 | — | C | 0.684 |
| 8 | ERR2278864 | — | — | 0.675 |
| 9 | TCGA-CQ-5330-01A-01R-1686-07 | — | — | 0.674 |
| 10 | SRR27320698 | — | — | 0.671 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.520 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.150 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.140 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.110 | Inavolisib | — uncovered |
| COAGULATION | 0.070 | Binimetinib | — uncovered |